رشدي محمد كامل
أستاذ مساعد
Efficacy of pulsed electromagnetic field therapy on acute radiodermatitis in breast cancer patients: a randomized controlled study
Supportive Care in Cancer • 2026
معلومات البحث
المؤلفون
Mahmoud Hamada Mohamed, Mohamed N. Selim, Marwa Elsayed Mohamed, Mohamed Magdy Elmeligie, Ahmed Mahmoud Kadry, Reda Kotb Abdelrazik, Sara Mohamed Samir, Roshdy Mohamed Kamel, Kamaleldin Ahmed kamal, Mahmoud Elshazly
الكلمات المفتاحية
Pulsed electromagnetic field, Hypo-fractionated whole breast irradiation, Sonography, Radiation Therapy
Oncology Group
المجلة العلمية
Supportive Care in Cancer
الناشر
Springer
المجلد
34
العدد
168
الصفحات
1-9
publication.type
International
رابط البحث
Open Link
المواد المرفقة
Not Available
الملخص
Purpose The objective of this research was to synthesize the evidence about the usage of pulsed electromagnetic field
(PEMF) in women with breast cancer undergoing hypo-fractionated whole-breast irradiation (HFWBI) for the treatment of
acute radiodermatitis.
Methods The study included 50 patients (35–55 years) with unilateral breast cancer post-lumpectomy who received HFWBI.
They were randomized into Group A (PEMF plus standard skin care) and Group B (standard skin care only). Skin reactions
were assessed during PEMF therapy using sonographic skin thickness measurements and RTOG criterion.
Results After radiation, skin thickness increased in both groups, peaking at 4 weeks (PEMF 2.82 mm; control 2.74 mm,
p = 0.030). By 6 weeks, thickness declined in the PEMF group but remained high in controls (p < 0.001), and by 8 weeks
PEMF returned near baseline (2.01 mm) while controls stayed thickened (p < 0.001). Skin reactions worsened in both groups
by week 4, with more severe cases in controls (36% vs. 12%, p = 0.150). By week 6, PEMF patients mostly had mild reactions
(72% Grade 0–1) compared to predominantly severe reactions in controls (84% Grade 2–3, p = 0.001). At 8 weeks, recovery
was greater with PEMF, as 52% returned to Grade 0 versus only 8% in controls (p = 0.001).
Conclusion Results such as these indicate that PEMF therapy accelerates recovery from radiotherapy and diminishes the
intensity of acute radiodermatitis.
Trial registration Trial registration number: NCT06003764. Date of registration: 12 August 2023. Prospectively registered
for prospectively registered trials.
(PEMF) in women with breast cancer undergoing hypo-fractionated whole-breast irradiation (HFWBI) for the treatment of
acute radiodermatitis.
Methods The study included 50 patients (35–55 years) with unilateral breast cancer post-lumpectomy who received HFWBI.
They were randomized into Group A (PEMF plus standard skin care) and Group B (standard skin care only). Skin reactions
were assessed during PEMF therapy using sonographic skin thickness measurements and RTOG criterion.
Results After radiation, skin thickness increased in both groups, peaking at 4 weeks (PEMF 2.82 mm; control 2.74 mm,
p = 0.030). By 6 weeks, thickness declined in the PEMF group but remained high in controls (p < 0.001), and by 8 weeks
PEMF returned near baseline (2.01 mm) while controls stayed thickened (p < 0.001). Skin reactions worsened in both groups
by week 4, with more severe cases in controls (36% vs. 12%, p = 0.150). By week 6, PEMF patients mostly had mild reactions
(72% Grade 0–1) compared to predominantly severe reactions in controls (84% Grade 2–3, p = 0.001). At 8 weeks, recovery
was greater with PEMF, as 52% returned to Grade 0 versus only 8% in controls (p = 0.001).
Conclusion Results such as these indicate that PEMF therapy accelerates recovery from radiotherapy and diminishes the
intensity of acute radiodermatitis.
Trial registration Trial registration number: NCT06003764. Date of registration: 12 August 2023. Prospectively registered
for prospectively registered trials.
